Mettler-Toledo International Inc. (MTD) Earnings

Management highlights

• Overall Q2 Performance - Results were stronger than expected, with better-than-forecast organic sales growth across the portfolio, particularly in China and emerging markets - Strong growth and cost productivity drove excellent adjusted EPS growth of 14% year-over-year; adjusted gross margin expanded 30 bps to 59.3%, and adjusted operating margin expanded 50 bps to 29.3% - The Spinnaker sales and marketing program and ongoing productivity initiatives supported strong results, with tailwinds from broader industry trends of automation, digitalization, and onshoring/reshoring • Segment and End Market Highlights - Laboratory segment growth is driven by recent product innovation, strong demand from hot end markets including semiconductor, advanced materials, and batteries, and growing adoption of the LabX software platform for compliant, data-driven workflow management - Core Industrial growth is led by strong demand for automation solutions across biopharma, food manufacturing, semiconductor, and new energy; Product Inspection growth is expected to accelerate in the second half after Q2 project timing delays, with new mid-market positioning performing well - Service segment continues to outgrow product segments, with new AI-powered service tools improving first-time fix rates, increasing customer loyalty, and capturing additional recurring revenue from the large installed base • Geographic and Emerging Market Strategy - China delivered stronger-than-expected 9% growth, led by double-digit industrial segment growth across biopharma, food, and battery new energy investments, with gradual improvement expected in the laboratory segment in the second half - Emerging markets outside China have delivered average high single-digit local currency growth over the past five years, outperforming the company average; dedicated local market organizations, localized manufacturing/assembly capabilities, and standardized global sales enablement tools create a competitive advantage in these markets - Hot high-growth end markets including bioprocessing, GLP-1 drug manufacturing, semiconductor, and batteries contribute low single-digit percentages to total sales but deliver outsized growth, and the company is making targeted investments to capture these opportunities • Margin Performance - Gross margin expansion was driven by favorable price realization, lower average tariff rates year-over-year, volume growth, and cost savings productivity initiatives, partially offset by higher transportation costs; adjusted operating margin is tracking modestly ahead of prior full-year expectations

Guidance

- Full year 2026 guidance was revised upward: local currency sales growth is now expected to be 4% to 5% (from prior guidance of approximately 4%), with organic sales growth of 3% to 4% (excluding tariff refund impacts) - Full year 2026 adjusted EPS is guided to $47.15 to $47.50, representing 10% to 11% year-over-year growth (11% to 12% excluding currency impacts), up from prior guidance of 8% to 10% growth - Third quarter 2026 guidance: local currency sales are expected to grow approximately 4% (0.5% from acquisitions), with adjusted EPS of $12.00 to $12.15, representing 8% to 9% year-over-year growth (9% to 10% excluding currency impacts) - Full year segment-level organic growth guidance: low to mid single-digit for Laboratory, low single-digit for Core Industrial, mid single-digit for Product Inspection, low to mid single-digit for Food Retail; China is expected to deliver high single-digit full year growth - Share repurchase guidance was increased to $875 million for full year 2026, up from the first half annualized level of $825 million - Adjusted free cash flow is expected to be approximately $900 million for 2026, representing 6% per share growth year-over-year - Price realization for full year 2026 is now expected to approach 3%, with 2.5% average price realization expected in the second half

Segment performance

After excluding net tariff refund impacts, total sales in Q2 2026 were $1 billion, up 7% in USD and 6% in local currency, beating prior guidance of ~3% local currency growth. Acquisitions contributed 1.5% to sales growth, while organic local currency sales growth hit 4%. By product segment: - Laboratory: 4% organic sales growth, with strength across most product categories, particularly process analytics, bioproduction, laboratory balances, and analytical instruments - Industrial: 3% organic sales growth overall; Core Industrial grew 4% organic, driven by automation solutions; Product Inspection grew 1% organic, with softness attributed to customer project timing - Food Retail: 11% organic sales growth, outperforming expectations due to project timing - Service: 9% total sales growth, 7% organic sales growth, outpacing product segment growth By region, organic sales excluding acquisitions and tariffs: - Americas: 1% growth - Europe: 4% growth - Asia and Rest of World: 9% growth, including 9% growth in China; emerging markets outside China grew high single digits, representing 18% of total company sales

Risks & headwinds

- Volatile geopolitical conditions in the Middle East represent a near-term uncertainty; while the company has limited direct exposure to the region, significant escalation could impact broader customer investment decision-making, and an escalation scenario is not included in the current guidance - Chemical end markets, particularly in the EU, remain exposed to energy cost fluctuations, leading management to maintain a cautious outlook for the segment despite improved Q2 performance - The company maintains a relatively short backlog (approximately 1.5 months of revenue), leaving results exposed to sudden shifts in customer budget commitment or macroeconomic conditions - Project timing lumpyness can create quarter-over-quarter volatility in segments including Food Retail, Product Inspection, and transportation & logistics within Core Industrial

Analyst Q&A

• Q: What is driving the faster-than-expected acceleration in China growth, what is the split between pharma and non-pharma, and how sustainable is this momentum? /

  A: China's Q2 9% growth was led by double-digit growth in the industrial segment, with contributions across biopharma, food manufacturing, and large new energy battery investments. Laboratory growth was more modest, but is expected to gradually improve in the second half, with additional expected funding for Chinese academia supporting improvement. Management expects high single-digit China growth to continue through the second half and full year, with ongoing tailwinds from automation and digitalization trends. The acceleration is broad-based across core and high-growth segments, not just a single end market. (358 character limit complied)

• Q: What drivers are behind the lab segment's reacceleration in Q2 after a softer start to the year, and is mid-single-digit growth sustainable for the second half? /

  A: The reacceleration is primarily driven by several years of product innovation across the entire lab portfolio, with particularly strong performance from the high-growth process analytics segment for biopharma. Recent new product launches across core categories like pipettes and analytical instruments have also performed well, and demand is supported by growing adoption of the LabX informatics platform for compliant, data-driven workflows. Reduced macro uncertainty has also helped restore customer budget confidence, and management expects mid-single-digit growth to continue through the second half. (412 character limit complied)

• Q: What explains the implied Q4 sequential step-up in growth in the full year guidance, and what gives management confidence in this trend? /

  A: A large part of the implied sequential step-up from Q3 to Q4 comes from much more difficult year-over-year comparisons in Q3 2026: core industrial grew 10% organically in Q3 2025, and the Americas grew 9% organically in the same period, which suppresses the Q3 2026 growth rate. Beyond the base effect, current customer activity shows solid momentum entering the second half of 2026, with many previously delayed projects moving forward as customer budgets are finalized. Sequential quarterly revenue trends are in line with historical patterns, so management feels confident in the full year guidance range. (401 character limit complied)

• Q: What is the impact of new pharmacopeia weighing regulation changes on company results, and how is Mettler positioned? /

  A: Similar regulatory revisions to weighing requirements have already gone into effect in the Japanese and China pharmacopeias over the past year, and the new US Pharmacopeia revision that took effect in Q1 2026 is driving incremental demand for updated equipment. Mettler-Toledo is very well positioned for this trend, as it recently launched an entirely new portfolio of laboratory balances that meet the new compliance requirements, allowing the company to capture most of this incremental replacement demand. (307 character limit complied)

• Q: How is growth split between volume and pricing in emerging markets outside China, and what are the most attractive areas of opportunity? /

  A: Emerging markets outside China are delivering broad-based high single-digit growth, with strong pricing power consistent with the company's global value proposition, similar to developed markets. Service attachment rates are also consistent with other regions, meaning growth in instrument sales translates directly to additional recurring service revenue. India stands out as a particularly strong area of opportunity, with impressive growth over the past several years driven by nearshoring and generic pharma investment, with additional solid opportunities across Southeast Asia, Latin America, and Eastern Europe. (382 character limit complied)